A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces

Completed · Phase 2

Conditions studied: Mucinous Gastrointestinal Adenocarcinoma

In brief

This is a Phase II open-label trial evaluating the efficacy, and safety of Erbitux in patients with mucinous gastrointestinal adenocarcinoma involving the peritoneal surface.

Key facts

Study ID

NCT00162110

Run by

Eli Lilly and Company

People needed

40

Starts

2004-11-01

Expected to finish

2007-01-01

Last updated by the study team

2015-10-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Able to take care of self. Out of bed less than 50% of the day
• Absolute neutrophil count >=1,500
• Platelet count >=100,000
• Total bilirubin count <=1.5 times the upper limit of normal

You may not qualify if…

• Prior epidermal growth factor receptor antibody
• Prior treatment with Erbitux
• Other cancers

Where it is running

• Local Institution — New York, New York, United States
• Local Institution — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.